Study people who took palbociclib prescriptions
Treatments studied
Part of Cancer, Skin clinical trials.
This study uses prescription records to learn about real-world use of palbociclib (a cancer medicine). You may be included if you’re an adult and have filled at least one palbociclib prescription.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have filled at least one prescription for palbociclib.
- You will be included based on pharmacy prescription records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a drug called palbociclib, which is a targeted therapy for a certain type of breast cancer. It aims to understand how often it causes low white blood cell counts (neutropenia) and how that affects treatment success. If you have metastatic HR+/HER2- breast cancer and haven't been treated for it yet, this trial may be a good fit.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Hear when a new Malignant Neoplasm of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.